HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levchenko, A. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Levchenko, A. Articles by Larson, S. M.

Evaluation of ¹¹C-Colchicine for PET Imaging of Multiple Drug Resistance

Nuclear Medicine Research Laboratory and Service, Department of Medical Physics, and Radiochemistry Laboratory, Memorial Sloan-Kettering Cancer Center, New York
Center for Biomedical Engineering, Columbia University, New York, New York

Correspondence: For correspondence or reprints contact: Bipin M. Mehta, PhD, Nuclear Medicine Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

ABSTRACT

Overexpression of P-glycoprotein (P-gp) can confer multiple drug resistance (MDR) phenotype on cancer cells and tumors by reducing intracellular accumulation of various cytotoxic agents. Early diagnosis of MDR in the clinic will serve to improve the efficacy of chemotherapeutic intervention and the quality of life of patients. In this article we describe use of a positron-emitting MDR tracer, ¹¹C-colchicine (CHC), to evaluate MDR by PET imaging. Unlike existing MDR tracers such as ^99mTc-sestamibi, this compound is electroneutral, with biodistribution not affected by perturbations of membrane potential. Methods: In vitro studies showed that resistance to CHC is correlated to resistance to Taxol (paclitaxel). The results of biodistribution experiments were found to be consistent with previously reported experiments with CHC labeled with other isotopes. On the basis of in vitro experiments with a series of drug-resistant variants of the human neuroblastoma BE (2)-C cell line, a mathematic model of ¹¹C-CHC distribution in tumors was formulated. Dynamic PET ¹¹C-CHC imaging experiments were performed with nude rats xeno-grafted with the BE (2)-C-sensitive and -resistant strains. Each scan was accompanied by a transmissions scan and a static FDG scan. These scans allowed improved image localization. Results: We observed an approximately 2-fold difference between ¹¹C-CHC accumulation in sensitive and resistant tumors. Imaging data were analyzed using the mathematic model, and various parameters characterizing resistance could be identified and estimated. In particular, the parameter r, proportional to the level of resistance of the tumors, was obtained. We showed that the ratio of these r parameters determined from the sensitive and resistant tumors was identical to the ratio of CHC accumulation in the corresponding sensitive and resistant cell lines used for xenografting. Conclusion: These in vivo experiments provided additional evidence for the indirect effect of P-gp action on CHC-to-tubulin binding, which in turn determines CHC uptake in tumors. The significance of these findings and future plans is discussed.

Key Words: multiple drug resistance • colchicine • PET • mathematic model

This article has been cited by other articles:

				D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]

				K. Ishiwata, K. Kawamura, K. Yanai, and N. H. Hendrikse In Vivo Evaluation of P-Glycoprotein Modulation of 8 PET Radioligands Used Clinically J. Nucl. Med., January 1, 2007; 48(1): 81 - 87. [Abstract] [Full Text] [PDF]

				V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier J. Nucl. Med., February 1, 2005; 46(2): 354 - 364. [Abstract] [Full Text] [PDF]

				S. H. Britz-Cunningham and S. J. Adelstein Molecular Targeting with Radionuclides: State of the Science J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961. [Abstract] [Full Text] [PDF]

				K. A. Kurdziel, D. O. Kiesewetter, R. E. Carson, W. C. Eckelman, and P. Herscovitch Biodistribution, Radiation Dose Estimates, and In Vivo Pgp Modulation Studies of 18F-Paclitaxel in Nonhuman Primates J. Nucl. Med., August 1, 2003; 44(8): 1330 - 1339. [Abstract] [Full Text] [PDF]

				D. E. Lorke, M. Krüger, R. Buchert, K. H. Bohuslavizki, M. Clausen, and U. Schumacher In Vitro and In Vivo Tracer Characteristics of an Established Multidrug-Resistant Human Colon Cancer Cell Line J. Nucl. Med., April 1, 2001; 42(4): 646 - 654. [Abstract] [Full Text]